Response to Comments: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia

This policy (A59354) is a response-to-comments notice regarding MolDX LCD DL39264 and does not itself define clinical coverage criteria. It records the comment period (2022-04-28 to 2022-06-11), the notice period start (2023-04-13), and the LCD effective date (2023-05-28); review LCD DL39264 for the specific indications, limitations, documentation, and frequency rules.

"This document is a response to comments for MolDX Local Coverage Determination DL39264 (MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia); the c..."

Sign up to see full coverage criteria, indications, and limitations.